MX339685B - Formulaciones de (trimetoxifenilamino) pirimidinilo nuevas. - Google Patents

Formulaciones de (trimetoxifenilamino) pirimidinilo nuevas.

Info

Publication number
MX339685B
MX339685B MX2014001065A MX2014001065A MX339685B MX 339685 B MX339685 B MX 339685B MX 2014001065 A MX2014001065 A MX 2014001065A MX 2014001065 A MX2014001065 A MX 2014001065A MX 339685 B MX339685 B MX 339685B
Authority
MX
Mexico
Prior art keywords
trimethoxyphenylamino
pyrimidinyl
formulations
new
hydrate
Prior art date
Application number
MX2014001065A
Other languages
English (en)
Other versions
MX2014001065A (es
Inventor
Abdul Karim Alhusban Farhan
Paul Gabbott Ian
Gururajan Bindhumadhavan
Sievwright Dawn
Bradley Brook Simpson David
Original Assignee
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46875902&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX339685(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc
Publication of MX2014001065A publication Critical patent/MX2014001065A/es
Publication of MX339685B publication Critical patent/MX339685B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporcionan composiciones farmacéuticas que comprenden mas de un 15% p/p del compuesto de Fórmula (I), según se define en la presente, y/o un hidrato de este y una cantidad de uno o mas agentes efervescentes que sea suficiente para proporcionar una disolución satisfactoria in vitro; y que comprenden además uno o más ingredientes farmacéuticamente aceptables; y procesos para obtenerlas.
MX2014001065A 2011-07-28 2012-07-26 Formulaciones de (trimetoxifenilamino) pirimidinilo nuevas. MX339685B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161512621P 2011-07-28 2011-07-28
PCT/GB2012/051791 WO2013014454A1 (en) 2011-07-28 2012-07-26 New (trimethoxyphenylamino)pyrimidinyl formulations

Publications (2)

Publication Number Publication Date
MX2014001065A MX2014001065A (es) 2014-08-01
MX339685B true MX339685B (es) 2016-06-06

Family

ID=46875902

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014001065A MX339685B (es) 2011-07-28 2012-07-26 Formulaciones de (trimetoxifenilamino) pirimidinilo nuevas.

Country Status (27)

Country Link
US (2) US8771648B2 (es)
EP (1) EP2736487B2 (es)
JP (1) JP6019116B2 (es)
KR (2) KR102090440B1 (es)
CN (1) CN103826610B (es)
AR (1) AR087371A1 (es)
AU (1) AU2012288632B2 (es)
BR (1) BR112014001999B1 (es)
CA (1) CA2843138C (es)
CY (1) CY1122596T1 (es)
DK (1) DK2736487T4 (es)
EA (1) EA028432B1 (es)
ES (1) ES2710423T3 (es)
FI (1) FI2736487T4 (es)
HK (1) HK1198741A1 (es)
HR (1) HRP20190186T1 (es)
HU (1) HUE042611T2 (es)
LT (1) LT2736487T (es)
MX (1) MX339685B (es)
PL (1) PL2736487T3 (es)
PT (1) PT2736487T (es)
RS (1) RS58433B1 (es)
SI (1) SI2736487T1 (es)
TR (1) TR201901792T4 (es)
TW (1) TW201311251A (es)
UY (1) UY34223A (es)
WO (1) WO2013014454A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5264759B2 (ja) * 2006-11-21 2013-08-14 ライジェル ファーマシューティカルズ， インコーポレイテッド ２，４−ピリミジンジアミン化合物のプロドラッグ塩およびそれらの使用
LT2736487T (lt) 2011-07-28 2019-02-25 Rigel Pharmaceuticals, Inc. Naujos (trimetoksifenilamino)pirimidinilo kompozicijos
ES2827323T3 (es) 2015-04-02 2021-05-20 Stora Enso Oyj Composición de lignina activada, método de fabricación de la misma y uso de la misma
WO2016172053A1 (en) 2015-04-24 2016-10-27 Rigel Pharmaceuticals, Inc. Methods of treating ibrutinib-resistant disease
MX2023000292A (es) * 2020-07-07 2023-02-09 Celgene Corp Composiciones farmaceuticas que comprenden (s)-4-(4-(4-(((2-(2,6-d ioxopiperidin-3-il)-1-oxoisoindolin-4-il)oxi)metil)bencil)piperaz in-1-il)-3-fluorobenzonitrilo y metodos de uso de las mismas.
CN116157023A (zh) * 2020-07-24 2023-05-23 帝斯曼知识产权资产管理有限公司 新型速溶片剂

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
DK1342470T5 (da) † 2002-03-04 2008-04-07 Orbus Pharma Inc Cefuroxim-axetil-sammensætninger med hurtig frigivelse
IL166241A0 (en) 2002-07-29 2006-01-15 Rigel Pharmaceuticals Inc Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds
KR101201603B1 (ko) 2003-07-30 2012-11-14 리겔 파마슈티칼스, 인크. 자가면역 질환의 치료 또는 예방에 사용하기 위한2,4-피리미딘디아민 화합물
US20050113398A1 (en) 2003-08-07 2005-05-26 Ankush Argade 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents
WO2006012502A2 (en) * 2004-07-23 2006-02-02 Rigel Pharmaceuticals, Inc. Formulation of insoluble small molecule therapeutics in lipid-based carriers
CA2580838A1 (en) * 2004-09-27 2006-04-06 Amgen Inc. Substituted heterocyclic compounds and methods of use
ES2333739T3 (es) † 2004-11-23 2010-02-26 Dong Wha Pharmaceutical Co., Ltd. Sal de n-hidroxi-4-(5-(4-(5-isopropil-2-metil-1,3-tiazol-4-il)fenoxi) pentoxi)benzamidina con acido 2-metanosulfonico.
NZ555947A (en) * 2005-01-19 2010-11-26 Rigel Pharmaceuticals Inc Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US8227455B2 (en) 2005-04-18 2012-07-24 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
EP1959961A2 (en) * 2005-12-06 2008-08-27 Rigel Pharmaceuticals, Inc. Formulation of insoluble small molecule therapeutics in lipid-based carriers
PL1984357T3 (pl) * 2006-02-17 2014-03-31 Rigel Pharmaceuticals Inc Związki 2,4-pirymidynodiaminy do leczenia lub zapobiegania chorób autoimmunologicznych
WO2008061201A1 (en) * 2006-11-15 2008-05-22 Rigel Pharmaceuticals, Inc. Methods for treating renal tumors using 2,4-pyrimidinediamine drug and prodrug compounds
JP5264759B2 (ja) * 2006-11-21 2013-08-14 ライジェル ファーマシューティカルズ， インコーポレイテッド ２，４−ピリミジンジアミン化合物のプロドラッグ塩およびそれらの使用
US20090012045A1 (en) * 2007-06-26 2009-01-08 Rigel Pharmaceuticals, Inc. Methods of Treating Cell Proliferative Disorders
US20090088371A1 (en) * 2007-08-28 2009-04-02 Rigel Pharmaceuticals, Inc. Combination therapy with syk kinase inhibitor
NZ585913A (en) * 2007-11-07 2012-06-29 Rigel Pharmaceuticals Inc Formulations and tablets comprising (6-(5-fluoro-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-ylamino)-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b][1,4]oxazin-4(3H)-yl)methyl phosphate (fostamatinib) disodium salt
ES2610880T3 (es) 2008-02-22 2017-05-03 Rigel Pharmaceuticals, Inc. Uso de 2,4-pirimidinadiaminas para el tratamiento de la aterosclerosis
UA108077C2 (xx) 2009-07-02 2015-03-25 Синтез динатрієвої солі n4-(2,2-диметил-4-$(дигідрофосфонокси)метил]-3-оксо-5-піридо$1,4]оксазин-6-іл)-5-фтор-n2-(3,4,5-триметоксифеніл)-2,4-піримідиндіаміну
US20110015155A1 (en) 2009-07-17 2011-01-20 Rigel Pharmaceuticals, Inc. Deuterated 2, 4-Pyrimidinediamine Compounds and Prodrugs Thereof and Their Uses
JP5681723B2 (ja) 2009-11-20 2015-03-11 ライジェル ファーマシューティカルズ， インコーポレイテッド ２，４−ピリミジンジアミン化合物およびそのプロドラッグならびにそれらの使用
WO2011130390A1 (en) 2010-04-13 2011-10-20 Rigel Pharmaceuticals, Inc. 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses
LT2736487T (lt) 2011-07-28 2019-02-25 Rigel Pharmaceuticals, Inc. Naujos (trimetoksifenilamino)pirimidinilo kompozicijos

Also Published As

Publication number Publication date
US20140271493A1 (en) 2014-09-18
CY1122596T1 (el) 2021-01-27
RS58433B1 (sr) 2019-04-30
KR20140058576A (ko) 2014-05-14
LT2736487T (lt) 2019-02-25
DK2736487T4 (da) 2024-11-04
DK2736487T3 (en) 2019-03-04
PT2736487T (pt) 2019-02-13
AU2012288632B2 (en) 2017-08-17
UY34223A (es) 2013-02-28
CN103826610B (zh) 2017-08-04
FI2736487T4 (fi) 2024-10-31
EA201490363A1 (ru) 2014-06-30
EA028432B1 (ru) 2017-11-30
EP2736487B1 (en) 2018-11-07
EP2736487A1 (en) 2014-06-04
JP2014521630A (ja) 2014-08-28
US8951504B2 (en) 2015-02-10
SI2736487T1 (sl) 2019-04-30
ES2710423T3 (es) 2019-04-25
MX2014001065A (es) 2014-08-01
TR201901792T4 (tr) 2019-03-21
KR102024120B1 (ko) 2019-09-23
AR087371A1 (es) 2014-03-19
US8771648B2 (en) 2014-07-08
US20130058876A1 (en) 2013-03-07
CN103826610A (zh) 2014-05-28
KR102090440B1 (ko) 2020-03-17
BR112014001999B1 (pt) 2023-11-28
PL2736487T3 (pl) 2019-06-28
HK1198741A1 (en) 2015-06-05
HRP20190186T1 (hr) 2019-03-22
JP6019116B2 (ja) 2016-11-02
HUE042611T2 (hu) 2019-07-29
WO2013014454A1 (en) 2013-01-31
KR20190109576A (ko) 2019-09-25
TW201311251A (zh) 2013-03-16
EP2736487B2 (en) 2024-08-28
CA2843138C (en) 2020-06-02
BR112014001999A2 (pt) 2017-02-21
AU2012288632A1 (en) 2014-02-20
CA2843138A1 (en) 2013-01-31

Similar Documents

Publication Publication Date Title
HK1138840A1 (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
MX2009010170A (es) Formulaciones topicas que tienen biodisponibilidad aumentada.
MX2011010311A (es) Formulaciones farmaceuticas que comprenden derivados de nitrocatecol y metodos para hacer las mismas.
MX348823B (es) Formulaciones estables de linaclotida.
MX2014001065A (es) Formulaciones de (trimetoxifenilamino) pirimidilino nuevas.
NZ708593A (en) Novel pyrazole derivative
MX340360B (es) Formulaciones farmaceuticas que comprenden derivados de nitrocatecol y metodos para hacer las mismas.
MX2014000130A (es) Procedimientos y composiciones para la inhibicion de resorcion osea.
MX2010014234A (es) Compuestos pirazol 436.
IN2014MN01754A (es)
CA2818187C (en) Bromodomain inhibitors and uses thereof
MX2019012939A (es) Formulaciones que contienen linaclotida para administracion oral.
MD4556C1 (ro) Compuşi inhibitori ai activităţii catehol O-metiltransferazei
MA34055B1 (fr) Chlorhydrate d'agomelatine hydrate et sa preparation
MY174090A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
GB2523707A (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
IN2014DN01619A (es)
MX342859B (es) Polisacarido de las semillas de tamarindo para usarse en el tratamiento de enfermedades inflamatorias.
TW200833335A (en) New pyridine analogues
IN2014MN02156A (es)
MY171526A (en) Pharmaceutical formulation for reducing frequency of urination and method of use thereof
TW200833333A (en) New pyridine analogues
EA032913B1 (ru) Препараты производных пиримидиндиона
PH12015501389A1 (en) Pharmaceutical formulation of n- [5-[2-(3,5-dimethoxyphenyl) ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl] benzamide
IN2014MN02433A (es)

Legal Events

Date Code Title Description
FG Grant or registration